Device-based Rate Versus Rhythm Control in Symptomatic Recent-onset Atrial Fibrillation (RACE 9 OBSERVE-AF)
Device-based Rate Versus Rhythm Control Treatment in Patients With Symptomatic Recent-onset Atrial Fibrillation in the Emergency Department (RACE 9 OBSERVE-AF)
Maastricht University Medical Center
490 participants
Nov 16, 2020
INTERVENTIONAL
Conditions
Summary
Continuous heart rhythm monitoring elucidated the recurrent and transient nature of recent-onset atrial fibrillation (AF). The RACE7 ACWAS showed that a wait-and-see approach (WAS) in patients with recent-onset AF (rate control for symptom relief followed by delayed cardioversion if needed \<48h) allows spontaneous conversion to sinus rhythm in 69% of patients, obviating active cardioversion. Recurrences within one month were seen in 30% of patients in both groups, i.e. the initially chosen strategy did not affect the recurrence pattern. Considering the latter, it remains unclear whether cardioversion is needed at all, especially since cardioversion strategy does not seem to affect behaviour of the arrhythmia over time. Instead of cardioversion a watchful-waiting rate control strategy may be appropriate as initial strategy. This allows observing the electrical and clinical behavior of arrhythmia, providing a solid basis for comprehensive and effective early rhythm control. This study is a multi-center clinical randomized controlled trial to show non-inferiority of watchful-waiting with rate control versus routine care in terms of prevalence of sinus rhythm at 4 weeks follow-up, using a novel telemonitoring infrastructure to guide rate control during follow-up.
Eligibility
Inclusion Criteria6
- ECG with atrial fibrillation
- Duration of the current AF episode \<36 hours
- Symptoms due to atrial fibrillation
- Age \> 18 years
- Able and willing to sign informed consent
- Able and willing to use telemetric rhythm recorder
Exclusion Criteria9
- History of persistent AF (episode of AF lasting more than 48 hours and terminated by cardioversion)
- Deemed unsuitable for participation by attending physician
- Hemodynamic instability (heart rate \>170 bpm, systolic blood pressure \<100 mmHg)
- Acute heart failure
- Signs of myocardial infarction
- History of syncope of unexplained origin
- History of untreated Sick Sinus Syndrome
- History of untreated Wolff-Parkinson-White syndrome
- Currently enrolled in another clinical trial
Interventions
Rate control drugs are administered to obtain symptom relief and a heart rate of \<110 bpm, followed by a 4-week telemonitoring period.
Pharmacological or electrical cardioversion is performed to achieve restoration of sinus rhythm, either acutely or in a wait-and-see approach, all within 48 hours, and followed by a 4-week telemonitoring period.
Locations(14)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT04612335